Abiopharma

🔍 GRIFFIN MICHELLE RENEE (Director)

Company: Adaptive Biotechnologies Corp (ADPT)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 52,084 shares of Common Stock at $7.8 per share (Direct)
  Date: 2026-06-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 67,709.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 52,084 shares of Common Stock at $20.18 per share (Direct)
  Date: 2026-06-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,625.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 52,084 shares of Stock Option (right to buy) at $7.8 per share (Derivative)
  Date: 2026-06-25 | Code: M | Expires: 2029-04-23 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
• F3: The option was fully vested and exercisable.